292 related articles for article (PubMed ID: 26460027)
1. Systemic, postsymptomatic antisense oligonucleotide rescues motor unit maturation delay in a new mouse model for type II/III spinal muscular atrophy.
Bogdanik LP; Osborne MA; Davis C; Martin WP; Austin A; Rigo F; Bennett CF; Lutz CM
Proc Natl Acad Sci U S A; 2015 Oct; 112(43):E5863-72. PubMed ID: 26460027
[TBL] [Abstract][Full Text] [Related]
2. CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis.
Janzen E; Mendoza-Ferreira N; Hosseinibarkooie S; Schneider S; Hupperich K; Tschanz T; Grysko V; Riessland M; Hammerschmidt M; Rigo F; Bennett CF; Kye MJ; Torres-Benito L; Wirth B
Brain; 2018 Aug; 141(8):2343-2361. PubMed ID: 29961886
[TBL] [Abstract][Full Text] [Related]
3. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
[TBL] [Abstract][Full Text] [Related]
4. Rescue of gene-expression changes in an induced mouse model of spinal muscular atrophy by an antisense oligonucleotide that promotes inclusion of SMN2 exon 7.
Staropoli JF; Li H; Chun SJ; Allaire N; Cullen P; Thai A; Fleet CM; Hua Y; Bennett CF; Krainer AR; Kerr D; McCampbell A; Rigo F; Carulli JP
Genomics; 2015 Apr; 105(4):220-8. PubMed ID: 25645699
[TBL] [Abstract][Full Text] [Related]
5. Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy.
Zhou H; Meng J; Malerba A; Catapano F; Sintusek P; Jarmin S; Feng L; Lu-Nguyen N; Sun L; Mariot V; Dumonceaux J; Morgan JE; Gissen P; Dickson G; Muntoni F
J Cachexia Sarcopenia Muscle; 2020 Jun; 11(3):768-782. PubMed ID: 32031328
[TBL] [Abstract][Full Text] [Related]
6. Dual SMN inducing therapies can rescue survival and motor unit function in symptomatic ∆7SMA mice.
Kray KM; McGovern VL; Chugh D; Arnold WD; Burghes AHM
Neurobiol Dis; 2021 Nov; 159():105488. PubMed ID: 34425216
[TBL] [Abstract][Full Text] [Related]
7. The neuromuscular impact of symptomatic SMN restoration in a mouse model of spinal muscular atrophy.
Arnold W; McGovern VL; Sanchez B; Li J; Corlett KM; Kolb SJ; Rutkove SB; Burghes AH
Neurobiol Dis; 2016 Mar; 87():116-23. PubMed ID: 26733414
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarks.
Muinos-Bühl A; Rombo R; Janzen E; Ling KK; Hupperich K; Rigo F; Bennett CF; Wirth B
Neurobiol Dis; 2022 Sep; 171():105795. PubMed ID: 35724821
[TBL] [Abstract][Full Text] [Related]
9. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model.
Hua Y; Sahashi K; Hung G; Rigo F; Passini MA; Bennett CF; Krainer AR
Genes Dev; 2010 Aug; 24(15):1634-44. PubMed ID: 20624852
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy.
Passini MA; Bu J; Richards AM; Kinnecom C; Sardi SP; Stanek LM; Hua Y; Rigo F; Matson J; Hung G; Kaye EM; Shihabuddin LS; Krainer AR; Bennett CF; Cheng SH
Sci Transl Med; 2011 Mar; 3(72):72ra18. PubMed ID: 21368223
[TBL] [Abstract][Full Text] [Related]
11. Motor neuron cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic mouse models.
Hua Y; Liu YH; Sahashi K; Rigo F; Bennett CF; Krainer AR
Genes Dev; 2015 Feb; 29(3):288-97. PubMed ID: 25583329
[TBL] [Abstract][Full Text] [Related]
12. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.
Riessland M; Ackermann B; Förster A; Jakubik M; Hauke J; Garbes L; Fritzsche I; Mende Y; Blumcke I; Hahnen E; Wirth B
Hum Mol Genet; 2010 Apr; 19(8):1492-506. PubMed ID: 20097677
[TBL] [Abstract][Full Text] [Related]
13. Moving towards treatments for spinal muscular atrophy: hopes and limits.
Wirth B; Barkats M; Martinat C; Sendtner M; Gillingwater TH
Expert Opin Emerg Drugs; 2015 Sep; 20(3):353-6. PubMed ID: 25920617
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic strategies for spinal muscular atrophy: SMN and beyond.
Bowerman M; Becker CG; Yáñez-Muñoz RJ; Ning K; Wood MJA; Gillingwater TH; Talbot K;
Dis Model Mech; 2017 Aug; 10(8):943-954. PubMed ID: 28768735
[TBL] [Abstract][Full Text] [Related]
15. A large animal model of spinal muscular atrophy and correction of phenotype.
Duque SI; Arnold WD; Odermatt P; Li X; Porensky PN; Schmelzer L; Meyer K; Kolb SJ; Schümperli D; Kaspar BK; Burghes AH
Ann Neurol; 2015 Mar; 77(3):399-414. PubMed ID: 25516063
[TBL] [Abstract][Full Text] [Related]
16. Motor unit recovery following Smn restoration in mouse models of spinal muscular atrophy.
Comley LH; Kline RA; Thomson AK; Woschitz V; Landeros EV; Osman EY; Lorson CL; Murray LM
Hum Mol Genet; 2022 Sep; 31(18):3107-3119. PubMed ID: 35551393
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model.
Sheng L; Rigo F; Bennett CF; Krainer AR; Hua Y
Nucleic Acids Res; 2020 Apr; 48(6):2853-2865. PubMed ID: 32103257
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Azithromycin Monohydrate as a Single or a Combinatorial Therapy in a Mouse Model of Severe Spinal Muscular Atrophy.
Osman EY; Washington CW; Simon ME; Megiddo D; Greif H; Lorson CL
J Neuromuscul Dis; 2017; 4(3):237-249. PubMed ID: 28598854
[TBL] [Abstract][Full Text] [Related]
19. Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy.
Cobb MS; Rose FF; Rindt H; Glascock JJ; Shababi M; Miller MR; Osman EY; Yen PF; Garcia ML; Martin BR; Wetz MJ; Mazzasette C; Feng Z; Ko CP; Lorson CL
Hum Mol Genet; 2013 May; 22(9):1843-55. PubMed ID: 23390132
[TBL] [Abstract][Full Text] [Related]
20. The effect of the DcpS inhibitor D156844 on the protective action of follistatin in mice with spinal muscular atrophy.
Harris AW; Butchbach ME
Neuromuscul Disord; 2015 Sep; 25(9):699-705. PubMed ID: 26055638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
